A Phase 3 interventional study of Tirzepatide and Dulaglutide in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 635 sites in 31 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 5 that started in 2020, is one of 17 in phase 3, and was the 16th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13,299 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one has the largest enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2020, is one of 85 in phase 3, and was the 158th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Established cardiovascular disease, including at least 1 of the following:
Coronary artery disease (CAD) with any of the following:
Cerebrovascular disease - any of the following:
Peripheral arterial disease with either of the following:
At the time of signing the : use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
Male patients: Men, regardless of their fertility status, with nonpregnant women of (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms, as well as 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug.
Female patients: Women of childbearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with males. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. Otherwise, WOCBP participating must agree to use 2 forms of effective contraception, where at least 1 form is highly effective (less than 1% failure rate), for the entirety of the study. Contraception must continue following completion of study drug administration for the entirety of the study and for 30 days thereafter.
Women not of childbearing potential may participate and include those who are:
In the investigator's opinion, are well motivated, capable, and willing to:
Exclusion Criteria:
Have a serum calcitonin level at screening of: (based on central laboratory results)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years.
Drug: Tirzepatide
Participants received 1.5 mg dulaglutide administered as SC injection QW for up to 5 years.
Drug: Dulaglutide
Administered SC
Also known as: LY3298176
Administered SC
Also known as: LY2189265
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to Occurrence of All-Cause Death
The number of participants from randomization to time to occurrence of Clinical Endpoint Committee (CEC) confirmed all-cause death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of all-cause death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time of Occurrence of CV Death
Number of participants from time of randomization to time to occurrence of CEC confirmed CV death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of CV death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)
The number of participants from randomization to first occurrence of CEC confirmed MI was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal MI during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization toTime to First Occurrence of Stroke
The number of participants from randomization to first occurrence of CEC confirmed stroke was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal stroke during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)
The number of participants from randomization to first occurrence of MACE-4 was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits
The number of participants from randomization to first occurrence of Clinical Endpoint Committee (CEC) confirmed heart failure requiring hospitalisation or urgent heart failure was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to First Occurrence of Revascularization
The number of participants from randomization to first occurrence of coronary revascularization was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of revascularization during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy
New or worsening nephropathy (Composite Endpoint 1) was defined as the first occurrence of any of the following events: persistent macroalbuminuria (urine albumin-to-creatinine ratio \>300 mg/g), persistent doubling of serum creatinine with eGFR \<45 mL/min/1.73 m², onset of end-stage renal disease (including initiation of chronic dialysis or kidney transplantation), or death due to renal disease. Time to event was defined as the number of days from the date of randomization to the first occurrence any of these events. during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
Time frame: From randomization (week 0) up to week 259
Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)
Change from baseline in eGFR calculated as difference between value at 36 months and baseline value. Participants included in this analysis were classified as having high or very high risk of chronic kidney disease at baseline based on their kidney function (eGFR) and urine albumin-to-creatinine ratio (UACR). High risk included participants with eGFR 45 to less than 60 milliliters/minutes/1.73 square metres (mL/min/1.73 m²) and UACR greater than 30 mg/g, or eGFR 60 mL/min/1.73 m² or higher with UACR greater than 300 mg/g. Very high risk included participants with eGFR less than 45 mL/min/1.73 m² or severely increased UACR (greater than 300 mg/g). These criteria are associated with an increased risk of worsening kidney function. Least squares (LS) mean was calculated using analysis of covariance (ANCOVA) model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline sodium-glucose cotransporter-2 (SGLT-2) Use Flag.
Time frame: Baseline, 36 Months
Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Change in HbA1c from baseline up to 36 months during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death. LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).
Time frame: Baseline, 36 Months
Percent Change From Baseline to 36 Months in Body Weight
LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares)
Time frame: Baseline, 36 Months
Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)
Urine samples were collected for the analysis of UACR. UACR (gram per kilograms \[g/kg\]) was calculated as urine albumin (gram per liter \[g/L\])/urine creatinine (kg/L). Percent change from baseline at 36 months was calculated as: \[(UACR at 36 months - baseline UACR) / baseline UACR\] × 100. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).
Time frame: Baseline, 36 Months
Percent Change From Baseline to 24 Months in Blood Lipids (Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG))
Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, LDL-C, HDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Percent change from baseline = 100\*(post-baseline assessment - baseline assessment)/baseline assessment. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag.
Time frame: Baseline, 24 Months
| Milestone | Tirzepatide - Maximum Tolerated Dose (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Started | 6648 | 6651 |
| Safety population | 6647 | 6647 |
| Modified intention-to-treat (mitt) population | 6586 | 6579 |
| Completed | 6524 | 6505 |
| Not completed | 124 | 146 |
| Withdrew: Withdrawal by subject | 17 | 15 |
| Withdrew: Lost to follow-up | 45 | 59 |
| Withdrew: Discontinued due to ''randomization in error'' | 62 | 72 |
Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] | 801 | 862 |
The number of participants from randomization to time to occurrence of Clinical Endpoint Committee (CEC) confirmed all-cause death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of all-cause death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to Occurrence of All-Cause Death | 566 | 669 |
Number of participants from time of randomization to time to occurrence of CEC confirmed CV death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of CV death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time of Occurrence of CV Death | 367 | 408 |
The number of participants from randomization to first occurrence of CEC confirmed MI was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal MI during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI) | 311 | 357 |
The number of participants from randomization to first occurrence of CEC confirmed stroke was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal stroke during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization toTime to First Occurrence of Stroke | 229 | 249 |
The number of participants from randomization to first occurrence of MACE-4 was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4) | 1089 | 1217 |
The number of participants from randomization to first occurrence of Clinical Endpoint Committee (CEC) confirmed heart failure requiring hospitalisation or urgent heart failure was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits | 512 | 557 |
The number of participants from randomization to first occurrence of coronary revascularization was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of revascularization during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to First Occurrence of Revascularization | 527 | 617 |
New or worsening nephropathy (Composite Endpoint 1) was defined as the first occurrence of any of the following events: persistent macroalbuminuria (urine albumin-to-creatinine ratio \>300 mg/g), persistent doubling of serum creatinine with eGFR \<45 mL/min/1.73 m², onset of end-stage renal disease (including initiation of chronic dialysis or kidney transplantation), or death due to renal disease. Time to event was defined as the number of days from the date of randomization to the first occurrence any of these events. during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.
| participants | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy | 373 | 442 |
Change from baseline in eGFR calculated as difference between value at 36 months and baseline value. Participants included in this analysis were classified as having high or very high risk of chronic kidney disease at baseline based on their kidney function (eGFR) and urine albumin-to-creatinine ratio (UACR). High risk included participants with eGFR 45 to less than 60 milliliters/minutes/1.73 square metres (mL/min/1.73 m²) and UACR greater than 30 mg/g, or eGFR 60 mL/min/1.73 m² or higher with UACR greater than 300 mg/g. Very high risk included participants with eGFR less than 45 mL/min/1.73 m² or severely increased UACR (greater than 300 mg/g). These criteria are associated with an increased risk of worsening kidney function. Least squares (LS) mean was calculated using analysis of covariance (ANCOVA) model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline sodium-glucose cotransporter-2 (SGLT-2) Use Flag.
| milliliters/minutes/1.73 square metres | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD) | -5.72 ± 0.437 | -8.90 ± 0.393 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Change in HbA1c from baseline up to 36 months during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death. LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).
| Percentage of HbA1c | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c) | -1.66 ± 0.0211 | -0.88 ± 0.0235 |
LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares)
| percent change | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Percent Change From Baseline to 36 Months in Body Weight | -11.6 ± 0.122 | -4.82 ± 0.0995 |
Urine samples were collected for the analysis of UACR. UACR (gram per kilograms \[g/kg\]) was calculated as urine albumin (gram per liter \[g/L\])/urine creatinine (kg/L). Percent change from baseline at 36 months was calculated as: \[(UACR at 36 months - baseline UACR) / baseline UACR\] × 100. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).
| percent change | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR) | -26.42 ± 1.202 | -7.23 ± 1.641 |
Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, LDL-C, HDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Percent change from baseline = 100\*(post-baseline assessment - baseline assessment)/baseline assessment. LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag.
| percent change | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| Total Cholesterol (TC) | -4.09 ± 0.318 | -2.78 ± 0.324 |
| Low-Density Lipoprotein Cholesterol (LDL-C) | -1.61 ± 0.562 | -2.87 ± 0.550 |
| High-Density Lipoprotein Cholesterol (HDL-C) | 9.34 ± 0.284 | 2.45 ± 0.266 |
| Triglycerides (TG) | -24.18 ± 0.453 | -10.17 ± 0.537 |
Collected over Baseline Up to 259 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide (MTD) | 568/6,648 (8.5%) | 2,117/6,647 (31.8%) | 4,718/6,647 (71%) |
| 1.5 mg Dulaglutide | 670/6,651 (10.1%) | 2,121/6,647 (31.9%) | 4,297/6,647 (64.6%) |
| Event | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| PneumoniaInfections and infestations | 126/6647 | 158/6647 |
| Acute kidney injuryRenal and urinary disorders | 93/6647 | 92/6647 |
| Covid-19Infections and infestations | 60/6647 | 85/6647 |
| Covid-19 pneumoniaInfections and infestations | 62/6647 | 67/6647 |
| Peripheral arterial occlusive diseaseVascular disorders | 59/6647 | 65/6647 |
| Angina unstableCardiac disorders | 63/6647 | 58/6647 |
| Cardiac failure chronicCardiac disorders | 62/6647 | 62/6647 |
| Atrial fibrillationCardiac disorders | 57/6647 | 55/6647 |
| Urinary tract infectionInfections and infestations | 57/6647 | 52/6647 |
| Cholecystitis acuteHepatobiliary disorders | 56/6647 | 42/6647 |
| Event | Tirzepatide (MTD) | 1.5 mg Dulaglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 1665/6647 | 1484/6647 |
| DiarrhoeaGastrointestinal disorders | 1644/6647 | 1258/6647 |
| Decreased appetiteMetabolism and nutrition disorders | 1136/6647 | 647/6647 |
| Covid-19Infections and infestations | 1041/6647 | 1005/6647 |
| ConstipationGastrointestinal disorders | 836/6647 | 771/6647 |
| VomitingGastrointestinal disorders | 757/6647 | 637/6647 |
| DyspepsiaGastrointestinal disorders | 658/6647 | 540/6647 |
| Weight decreasedInvestigations | 467/6647 | 117/6647 |
| Urinary tract infectionInfections and infestations | 442/6647 | 462/6647 |
| DizzinessNervous system disorders | 462/6647 | 407/6647 |
All randomized participants.
| Age, Continuous(years) | Tirzepatide (MTD) | 1.5 mg Dulaglutide | Total |
|---|---|---|---|
| Mean | 64.00 ± 8.83 | 64.10 ± 8.72 | 64.10 ± 8.77 |
| Sex: Female, Male(Participants) | Tirzepatide (MTD) | 1.5 mg Dulaglutide | Total |
|---|---|---|---|
| Female | 1903 | 1946 | 3849 |
| Male | 4745 | 4705 | 9450 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide (MTD) | 1.5 mg Dulaglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 2007 | 2003 | 4010 |
| Not Hispanic or Latino | 4326 | 4316 | 8642 |
| Unknown or Not Reported | 315 | 332 | 647 |
| Race (NIH/OMB)(Participants) | Tirzepatide (MTD) | 1.5 mg Dulaglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 489 | 481 | 970 |
| Asian | 580 | 590 | 1170 |
| Native Hawaiian or Other Pacific Islander | 9 | 9 | 18 |
| Black or African American | 111 | 109 | 220 |
| White | 5349 | 5348 | 10697 |
| More than one race | 22 | 26 | 48 |
| Unknown or Not Reported | 88 | 88 | 176 |
| Region of Enrollment(Participants) | Tirzepatide (MTD) | 1.5 mg Dulaglutide | Total |
|---|---|---|---|
| Argentina | 812 | 815 | 1627 |
| Australia | 194 | 194 | 388 |
| Austria | 41 | 40 | 81 |
| Belgium | 65 | 66 | 131 |
| Brazil | 310 | 312 | 622 |
| Canada | 227 | 227 | 454 |
| China | 175 | 175 | 350 |
| Czechia | 114 | 113 | 227 |
| France | 76 | 74 | 150 |
| Germany | 489 | 488 | 977 |
| Greece | 160 | 160 | 320 |
| Hungary | 188 | 187 | 375 |
| India | 117 | 118 | 235 |
| Israel | 214 | 214 | 428 |
| Italy | 108 | 109 | 217 |
| Japan | 50 | 50 | 100 |
| Mexico | 792 | 792 | 1584 |
| Netherlands | 63 | 65 | 128 |
| Poland | 224 | 223 | 447 |
| Romania | 282 | 283 | 565 |
| Russia | 177 | 178 | 355 |
| Slovakia | 81 | 82 | 163 |
| South Korea | 65 | 65 | 130 |
| Spain | 204 | 205 | 409 |
| Sweden | 49 | 48 | 97 |
| Taiwan | 81 | 79 | 160 |
| Turkey (Türkiye) | 126 | 124 | 250 |
| Ukraine | 375 | 375 | 750 |
| United Kingdom | 39 | 39 | 78 |
| United States | 750 | 751 | 1501 |
Showing the first 100 of 635 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2020 to primary completion in Jun 2025, 60 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 60 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide